VivoSeq
Oncology

Metastatic Colorectal Adenocarcinoma

12

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Metastatic Colorectal Adenocarcinoma is an emerging landscape with 12 programs across 7 companies. The most active players are Eastern Cooperative Oncology Group, Imclone, Pfizer. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

0/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 1I

Imclone

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1Roche logo

Roche

2 programs

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Teva logo

Teva

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

8 of 12 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody433%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Suspended1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer
Suspended·National Cancer Institute (NCI)·Phase 1·NCT06102902·30 enrolled
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02997228·120 enrolled
Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06696768·24 enrolled
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT05673148·364 enrolled
A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT07147231·86 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)